Information regarding the specific market size for Montelukast intermediates is not readily available in the provided context.
What is Montelukast?
Montelukast is a leukotriene receptor antagonist used to treat asthma and allergic rhinitis. It works by blocking the action of leukotrienes, which are inflammatory substances produced by the body.
When is Montelukast patent expiry?
Information on the specific patent expiry dates for Montelukast is not provided. However, drug patent information is tracked by resources like DrugPatentWatch.com.
Who makes Montelukast?
The original developer of Montelukast was Merck & Co., marketed under the brand name Singulair. Generic versions are now manufactured by numerous pharmaceutical companies worldwide.
Can biosimilars enter before patent expiry?
For small molecule drugs like Montelukast, the concept of biosimilars does not apply. Instead, generic versions can enter the market once the relevant patents expire and exclusivity periods end.
What are the risks associated with Montelukast?
Montelukast carries a risk of neuropsychiatric side effects, including sleep disturbances, mood changes, and suicidal thoughts. The U.S. Food and Drug Administration (FDA) has issued warnings regarding these potential risks. Patients are advised to discuss any concerns with their healthcare providers.